Skip to main content
SpringerLink
Log in

mTOR Inhibitors in Castration-Resistant Prostate Cancer: A Systematic Review

  • Systematic Review
  • Published:
Targeted Oncology Aims and scope Submit manuscript

Abstract

Background

The progression of prostate cancer to castration-resistant prostate cancer (CRPC) is often a result of somatic alterations in the PI3K/Akt/mTOR (mammalian target of rapamycin) pathway, suggesting that therapies targeting this pathway might lead to improved survival and efficacy. Here, we systematically evaluate the results of clinical trials investigating mTOR inhibition in CRPC and utilize preclinical data to predict clinical outcomes.

Methods

Trials included in the study were identified through PubMed and via review of conference abstracts cited by relevant review articles. The eligibility of trials was independent of sample size, clinical setting, or date.

Results

A total of 14 studies were eligible for qualitative analysis. The clinical setting was variable among studies, and all utilized an allosteric mTOR inhibitor as either a monotherapy or in combination. Molecular criteria were evaluated in three trials. Among most studies, the prostate-specific antigen level declined during treatment, but often increased shortly thereafter. Partial responses to treatment were minimal, and no complete responses were reported. Two studies exploring therapy with an mTOR inhibitor in combination with bicalutamide resulted in minimal efficacy. Overall, allosteric mTOR inhibition was deemed to be inadequate for the treatment of CRPC.

Conclusion

Preclinical data suggest that a reciprocal feedback mechanism between PI3K and androgen receptor signaling is a potential mechanism behind the clinical inefficacy of mTOR inhibitors in CRPC, indicating combinatorial targeting of PI3K, mTORC1/2, and the androgen receptor might be more effective. Comprehensive analysis of preclinical data to assess clinical trial targets and efficacy may reduce the number of unproductive trials and identify potentially beneficial combinatorial therapies for resistant disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. American Cancer Society. Cancer facts & figures 2016. Atlanta: American Cancer Society; 2016.

  2. Antonarakis ES, Feng Z, Trock BJ, Humphreys EB, Carducci MA, Partin AW, et al. The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up. BJU Int. 2012;109(1):32–9. doi:10.1111/j.1464-410X.2011.10422.x.

    Article  CAS  PubMed  Google Scholar 

  3. Lonergan PE, Tindall DJ. Androgen receptor signaling in prostate cancer development and progression. J Carcinog. 2011;10:20. doi:10.4103/1477-3163.83937.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Huggins C, Hodges CV. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol. 2002;168(1):9–12.

    Article  PubMed  Google Scholar 

  5. Edlind MP, Hsieh AC. PI3K-AKT-mTOR signaling in prostate cancer progression and androgen deprivation therapy resistance. Asian J Androl. 2014;16(3):378–86. doi:10.4103/1008-682X.122876.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC, et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA. 2005;294(4):433–9. doi:10.1001/jama.294.4.433.

    Article  CAS  PubMed  Google Scholar 

  7. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med. 2004;10(1):33–9. doi:10.1038/nm972.

    Article  PubMed  Google Scholar 

  8. Schweizer MT, Yu EY. Persistent androgen receptor addiction in castration-resistant prostate cancer. J Hematol Oncol. 2015;8(1):128. doi:10.1186/s13045-015-0225-2.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Anantharaman A, Friedlander TW. Targeting the androgen receptor in metastatic castrate-resistant prostate cancer: a review. Urol Oncol. 2016;34(8):356–67. doi:10.1016/j.urolonc.2015.11.003.

  10. Chan SC, Dehm SM. Constitutive activity of the androgen receptor. Adv Pharmacol. 2014;70:327–66. doi:10.1016/B978-0-12-417197-8.00011-0.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Montgomery RB, Mostaghel EA, Vessella R, Hess DL, Kalhorn TF, Higano CS, et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res. 2008;68(11):4447–54. doi:10.1158/0008-5472.CAN-08-0249.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell. 2010;18(1):11–22. doi:10.1016/j.ccr.2010.05.026.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Bitting RL, Armstrong AJ. Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer. Endocr Relat Cancer. 2013;20(3):R83–99. doi:10.1530/ERC-12-0394.

    Article  CAS  PubMed  Google Scholar 

  14. Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, et al. Integrative clinical genomics of advanced prostate cancer. Cell. 2015;161(5):1215–28. doi:10.1016/j.cell.2015.05.001.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Song MS, Salmena L, Pandolfi PP. The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol. 2012;13(5):283–96. doi:10.1038/nrm3330.

    CAS  PubMed  Google Scholar 

  16. Hahn-Windgassen A, Nogueira V, Chen CC, Skeen JE, Sonenberg N, Hay N. Akt activates the mammalian target of rapamycin by regulating cellular ATP level and AMPK activity. J Biol Chem. 2005;280(37):32081–9. doi:10.1074/jbc.M502876200.

    Article  CAS  PubMed  Google Scholar 

  17. Wang S, Gao J, Lei Q, Rozengurt N, Pritchard C, Jiao J, et al. Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell. 2003;4(3):209–21.

    Article  CAS  PubMed  Google Scholar 

  18. Nardella C, Carracedo A, Alimonti A, Hobbs RM, Clohessy JG, Chen Z, et al. Differential requirement of mTOR in postmitotic tissues and tumorigenesis. Sci Signal. 2009;2(55):ra2. doi:10.1126/scisignal.2000189.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Tai S, Sun Y, Liu N, Ding B, Hsia E, Bhuta S, et al. Combination of Rad001 (everolimus) and propachlor synergistically induces apoptosis through enhanced autophagy in prostate cancer cells. Mol Cancer Ther. 2012;11(6):1320–31. doi:10.1158/1535-7163.MCT-11-0954.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Fagone P, Donia M, Mangano K, Quattrocchi C, Mammana S, Coco M, et al. Comparative study of rapamycin and temsirolimus demonstrates superimposable anti-tumour potency on prostate cancer cells. Basic Clin Pharmacol Toxicol. 2013;112(1):63–9. doi:10.1111/j.1742-7843.2012.00923.x.

    Article  CAS  PubMed  Google Scholar 

  21. Li W, Wang Z, Wang L, He X, Wang G, Liu H, et al. Effectiveness of inhibitor rapamycin, saracatinib, linsitinib and JNJ-38877605 against human prostate cancer cells. Int J Clin Exp Med. 2015;8(4):6563–7.

    CAS  PubMed  PubMed Central  Google Scholar 

  22. Carver BS, Chapinski C, Wongvipat J, Hieronymus H, Chen Y, Chandarlapaty S, et al. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell. 2011;19(5):575–86. doi:10.1016/j.ccr.2011.04.008.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Lee SH, Johnson D, Luong R, Sun Z. Crosstalking between androgen and PI3K/AKT signaling pathways in prostate cancer cells. J Biol Chem. 2015;290(5):2759–68. doi:10.1074/jbc.M114.607846.

    Article  CAS  PubMed  Google Scholar 

  24. Patterson SE, Liu R, Statz CM, Durkin D, Lakshminarayana A, Mockus SM. The clinical trial landscape in oncology and connectivity of somatic mutational profiles to targeted therapies. Hum Genom. 2016;10(1):4. doi:10.1186/s40246-016-0061-7.

    Article  Google Scholar 

  25. Meng S, Cao J, He Q, Xiong L, Chang E, Radovick S, et al. Metformin activates AMP-activated protein kinase by promoting formation of the alphabetagamma heterotrimeric complex. J Biol Chem. 2015;290(6):3793–802. doi:10.1074/jbc.M114.604421.

    Article  CAS  PubMed  Google Scholar 

  26. Spratt DE, Zhang C, Zumsteg ZS, Pei X, Zhang Z, Zelefsky MJ. Metformin and prostate cancer: reduced development of castration-resistant disease and prostate cancer mortality. Eur Urol. 2013;63(4):709–16. doi:10.1016/j.eururo.2012.12.004.

    Article  CAS  PubMed  Google Scholar 

  27. Clyne M. Should we give metformin to all men with CRPC? Nat Rev Urol. 2014;11(2):63. doi:10.1038/nrurol.2014.7.

    Article  PubMed  Google Scholar 

  28. Raval AD, Thakker D, Vyas A, Salkini M, Madhavan S, Sambamoorthi U. Impact of metformin on clinical outcomes among men with prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2015;18(2):110–21. doi:10.1038/pcan.2014.52.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Amato RJ, Jac J, Mohammad T, Saxena S. Pilot study of rapamycin in patients with hormone-refractory prostate cancer. Clin Genitourin Cancer. 2008;6(2):97–102. doi:10.3816/CGC.2008.n.015.

    Article  CAS  PubMed  Google Scholar 

  30. Bhat M, Charlton M. Preserving flow in liver transplant recipients: mTOR inhibitors everolimus and sirolimus are not peas from a pod. Am J Transplant. 2013;13(7):1633–5. doi:10.1111/ajt.12290.

    Article  CAS  PubMed  Google Scholar 

  31. Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol. 2008;26(2):242–5. doi:10.1200/JCO.2007.12.4008.

    Article  CAS  PubMed  Google Scholar 

  32. Armstrong AJ, Shen T, Halabi S, Kemeny G, Bitting RL, Kartcheske P, et al. A phase II trial of temsirolimus in men with castration-resistant metastatic prostate cancer. Clin Genitourin Cancer. 2013;11(4):397–406. doi:10.1016/j.clgc.2013.05.007.

    Article  PubMed  Google Scholar 

  33. Kruczek K, Ratterman M, Tolzien K, Sulo S, Lestingi TM, Nabhan C. A phase II study evaluating the toxicity and efficacy of single-agent temsirolimus in chemotherapy-naive castration-resistant prostate cancer. Br J Cancer. 2013;109(7):1711–6. doi:10.1038/bjc.2013.530.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Emmenegger U, Booth CM, Berry S, Sridhar SS, Winquist E, Bandali N, et al. Temsirolimus maintenance therapy after docetaxel induction in castration-resistant prostate cancer. Oncologist. 2015;20(12):1351–2. doi:10.1634/theoncologist.2015-0220.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Aggarwal R, Ryan CJ. Castration-resistant prostate cancer: targeted therapies and individualized treatment. Oncologist. 2011;16(3):264–75. doi:10.1634/theoncologist.2010-0216.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Naing A, Kurzrock R, Burger A, Gupta S, Lei X, Busaidy N, et al. Phase I trial of cixutumumab combined with temsirolimus in patients with advanced cancer. Clin Cancer Res. 2011;17(18):6052–60. doi:10.1158/1078-0432.CCR-10-2979.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Rathkopf DE, Danila DC, Morris MJ, Slovin SF, Borwick LS, Momen L, et al. Anti-insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody cixutumumab (cix) plus mTOR inhibitor temsirolimus (tem) in metastatic castration-resistant prostate cancer (mCRPC): results of a phase I pilot study. J Clin Oncol. 2011;29(suppl; abstr e15081).

  38. Templeton AJ, Dutoit V, Cathomas R, Rothermundt C, Bartschi D, Droge C, et al. Phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 08/08). Eur Urol. 2013;64(1):150–8. doi:10.1016/j.eururo.2013.03.040.

    Article  CAS  PubMed  Google Scholar 

  39. Gross ME, Soscia J, Sakowsky S, Castellanos O, Agus DB. Phase I trial of RAD001 (R), bevacizumab (B), and docetaxel (D) for castration-resistant prostate cancer (CRPC). J Clin Oncol. 2009;27:15s(suppl; abstr 5154).

  40. Gross TBD ME, Quinn DI, Massopust K, Diaz PM, Castellanos OO, Agus DB. Safety and efficacy of everolimus (E), bevacizumab (B), and docetaxel (D) for castration resistant prostate cancer (CRPC). J Clin Oncol. 2015;33(suppl; abstr 5066).

  41. Nakabayashi M, Werner L, Courtney KD, Buckle G, Oh WK, Bubley GJ, et al. Phase II trial of RAD001 and bicalutamide for castration-resistant prostate cancer. BJU Int. 2012;110(11):1729–35. doi:10.1111/j.1464-410X.2012.11456.x.

    Article  CAS  PubMed  Google Scholar 

  42. Scher HI, Morris MJ, Basch E, Heller G. End points and outcomes in castration-resistant prostate cancer: from clinical trials to clinical practice. J Clin Oncol. 2011;29(27):3695–704. doi:10.1200/JCO.2011.35.8648.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Courtney KD, Manola JB, Elfiky AA, Ross R, Oh WK, Yap JT, et al. A phase I study of everolimus and docetaxel in patients with castration-resistant prostate cancer. Clin Genitourin Cancer. 2015;13(2):113–23. doi:10.1016/j.clgc.2014.08.007.

    Article  PubMed  Google Scholar 

  44. Edinger AL, Linardic CM, Chiang GG, Thompson CB, Abraham RT. Differential effects of rapamycin on mammalian target of rapamycin signaling functions in mammalian cells. Cancer Res. 2003;63(23):8451–60.

    CAS  PubMed  Google Scholar 

  45. Vaishampayan U, Shevrin D, Stein M, Heilbrun L, Land S, Stark K, et al. Phase II trial of carboplatin, everolimus, and prednisone in metastatic castration-resistant prostate cancer pretreated with docetaxel chemotherapy: a prostate cancer clinical trial consortium study. Urology. 2015;86(6):1206–11. doi:10.1016/j.urology.2015.08.008.

    Article  PubMed  Google Scholar 

  46. Rathkopf DE, Larson SM, Anand A, Morris MJ, Slovin SF, Shaffer DR, et al. Everolimus combined with gefitinib in patients with metastatic castration-resistant prostate cancer: phase 1/2 results and signaling pathway implications. Cancer. 2015;121(21):3853–61. doi:10.1002/cncr.29578.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Perotti A, Locatelli A, Sessa C, Hess D, Vigano L, Capri G, et al. Phase IB study of the mTOR inhibitor ridaforolimus with capecitabine. J Clin Oncol. 2010;28(30):4554–61. doi:10.1200/JCO.2009.27.5867.

    Article  CAS  PubMed  Google Scholar 

  48. Amato RJ, Wilding G, Bubley G, Loewy J, Haluska F, Gross ME. Safety and preliminary efficacy analysis of the mTOR inhibitor ridaforolimus in patients with taxane-treated, castration-resistant prostate cancer. Clin Genitourin Cancer. 2012;10(4):232–8. doi:10.1016/j.clgc.2012.05.001.

    Article  PubMed  PubMed Central  Google Scholar 

  49. Meulenbeld HJ, de Bono JS, Tagawa ST, Whang YE, Li X, Heath KH, et al. Tolerability, safety and pharmacokinetics of ridaforolimus in combination with bicalutamide in patients with asymptomatic, metastatic castration-resistant prostate cancer (CRPC). Cancer Chemother Pharmacol. 2013;72(4):909–16. doi:10.1007/s00280-013-2250-6.

    Article  CAS  PubMed  Google Scholar 

  50. Cockshott ID. Bicalutamide: clinical pharmacokinetics and metabolism. Clin Pharmacokinet. 2004;43(13):855–78.

    Article  CAS  PubMed  Google Scholar 

  51. Klumpen HJ, Beijnen JH, Gurney H, Schellens JH. Inhibitors of mTOR. Oncologist. 2010;15(12):1262–9. doi:10.1634/theoncologist.2010-0196.

    Article  PubMed  PubMed Central  Google Scholar 

  52. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351(15):1502–12. doi:10.1056/NEJMoa040720.

    Article  CAS  PubMed  Google Scholar 

  53. Petrylak DP, Tangen CM, Hussain MH, Lara Jr PN, Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351(15):1513–20. doi:10.1056/NEJMoa041318.

    Article  CAS  PubMed  Google Scholar 

  54. Chandrasekar T, Yang JC, Gao AC, Evans CP. Targeting molecular resistance in castration-resistant prostate cancer. BMC Med. 2015;13:206. doi:10.1186/s12916-015-0457-6.

    Article  PubMed  PubMed Central  Google Scholar 

  55. Trotman LC, Niki M, Dotan ZA, Koutcher JA, Di Cristofano A, Xiao A, et al. Pten dose dictates cancer progression in the prostate. PLoS Biol. 2003;1(3):E59. doi:10.1371/journal.pbio.0000059.

    Article  PubMed  PubMed Central  Google Scholar 

  56. Thomas C, Lamoureux F, Crafter C, Davies BR, Beraldi E, Fazli L, et al. Synergistic targeting of PI3K/AKT pathway and androgen receptor axis significantly delays castration-resistant prostate cancer progression in vivo. Mol Cancer Ther. 2013;12(11):2342–55. doi:10.1158/1535-7163.MCT-13-0032.

    Article  CAS  PubMed  Google Scholar 

  57. Chang L, Graham PH, Ni J, Hao J, Bucci J, Cozzi PJ, et al. Targeting PI3K/Akt/mTOR signaling pathway in the treatment of prostate cancer radioresistance. Crit Rev Oncol Hematol. 2015;96(3):507–17. doi:10.1016/j.critrevonc.2015.07.005.

    Article  PubMed  Google Scholar 

  58. Garcia-Echeverria C. Allosteric and ATP-competitive kinase inhibitors of mTOR for cancer treatment. Bioorg Med Chem Lett. 2010;20(15):4308–12. doi:10.1016/j.bmcl.2010.05.099.

    Article  CAS  PubMed  Google Scholar 

  59. Choi J, Chen J, Schreiber SL, Clardy J. Structure of the FKBP12–rapamycin complex interacting with the binding domain of human FRAP. Science. 1996;273(5272):239–42.

    Article  CAS  PubMed  Google Scholar 

  60. Ingels A, Zhao H, Thong AE, Saar M, Valta MP, Nolley R, et al. Preclinical trial of a new dual mTOR inhibitor, MLN0128, using renal cell carcinoma tumorgrafts. Int J Cancer. 2014;134(10):2322–9. doi:10.1002/ijc.28579.

    Article  CAS  PubMed  Google Scholar 

  61. Hsieh AC, Liu Y, Edlind MP, Ingolia NT, Janes MR, Sher A, et al. The translational landscape of mTOR signalling steers cancer initiation and metastasis. Nature. 2012;485(7396):55–61. doi:10.1038/nature10912.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Maira SM, Pecchi S, Huang A, Burger M, Knapp M, Sterker D, et al. Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor. Mol Cancer Ther. 2012;11(2):317–28. doi:10.1158/1535-7163.MCT-11-0474.

    Article  CAS  PubMed  Google Scholar 

  63. Attard G, Cooper CS, de Bono JS. Steroid hormone receptors in prostate cancer: a hard habit to break? Cancer Cell. 2009;16(6):458–62. doi:10.1016/j.ccr.2009.11.006.

    Article  CAS  PubMed  Google Scholar 

  64. Qi W, Morales C, Cooke LS, Johnson B, Somer B, Mahadevan D. Reciprocal feedback inhibition of the androgen receptor and PI3K as a novel therapy for castrate-sensitive and -resistant prostate cancer. Oncotarget. 2015;6(39):41976–87. doi:10.18632/oncotarget.5659.

    PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgments

We would like to thank Sara Cassidy and Susie Airhart for their assistance with review and editing of the article.

Author information

Authors and Affiliations

  1. The Jackson Laboratory for Genomic Medicine, 10 Discovery Drive, Farmington, CT, USA

    Cara M. Statz, Sara E. Patterson & Susan M. Mockus

Authors
  1. Cara M. Statz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sara E. Patterson
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Susan M. Mockus
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Susan M. Mockus.

Ethics declarations

Funding

None.

Conflict of Interest

The authors declare that they have no conflicts of interest.

Electronic supplementary material

Below is the link to the electronic supplementary material.

ESM 1

(XLSX 202 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Statz, C.M., Patterson, S.E. & Mockus, S.M. mTOR Inhibitors in Castration-Resistant Prostate Cancer: A Systematic Review. Targ Oncol 12, 47–59 (2017). https://doi.org/10.1007/s11523-016-0453-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11523-016-0453-6

Keywords

Search

Navigation